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Abstract
The new antiplatelets and anticoagulant drugs have been recently introduced in the daily medical practices for the 
control of thromboembolism associated with different diseases. The dental assistance of these patients forces us 
to know these drugs, understand their action mechanisms and try to decrease the risks that entail ours actions in 
these patients, making a thorough analysis of the risk of bleeding that is going to be related to our medical inter-
vention, as well as the use of all the control measures of the hemorrhage from our knowledge with these patients, 
and to be prudent. The communication with the medical specialist that supervises these patients must be maxim, 
being necessary to make clinic trials for establishing protocols or guides of the handling with these patients during 
the odontological treatment.
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Introduction
There are a large number of diseases with an increase of 
the risk of thrombosis. Between them the ones that stand 
out are: the cardiovascular diseases (ischemic heart dis-
ease, peripheral arterial disease, etc.), the neurological 
diseases (stroke, transient ischemic accident or TI�, 
etc.), certain arrhythmias like atrial fibrillation (AF), 
etc., surgeries that order prolonged immobilization, 
etc. For the prevention and control of these thrombotic 
risk there has been used the classics antiplatelets drugs 
(acetylsalicylic acid or �S�, clopidogrel, ticlodipine 
and dipyridamol) as well as the classics anticoagulants 
drugs (warfarin, acenocoumarol and heparin). In the 
last years there have been appearing new anticoagulants 
and antiplatelets drugs. With these new drugs the doc-
tors have wanted to increase the reaction time, have a 
better prediction about the effect that is wanted on the 
patients, reduce the secondary effects and minimize the 
possible pharmacological interactions of these. In this 
article we have tried to make a review of the main char-
acteristics of the antiplatelet and anticoagulant drugs 
with clinic application, as well as establish a guide of 
the use of the patients with this type of treatment when 
there are going to be made a dental treatments.
Bibliographic review antiplatelet drugs
-Classic antiplatelet drugs (1)
The old antiplatelets drugs are a heterogeneous group 
used for prevent that platelets do their physiological 
function. The platelets attend principally in primary he-
mostasis, and in the coagulation phase too. In the platelet 
activation act different enzymes: the cyclo-oxygenase, 
the phosphodiesterase and the adenosine diphosphate 
(�DP). The old antiplatelets act normally on different 
enzymes and substances, for example the classic inhi-
bitor of the cyglo-oxygenase is the acetylsalicylic acid 
(�S�), the inhibitor of phosphodiesterase is dipyrida-
mole and the �DP receptors blockers are clopidogrel 
and ticlopidine. �CETYLS�LICYLIC �CID  (�diro®, 
Bioplak®, Tromalyt®)
Is the non-steroidal anti-inflamatory and antiplatelet 
most used for the prevention of thromboembolic di-
seases. �S� produce an irreversible inhibition   of the 
platelet s´ cyglo-oxygenase. This enzyme acts in the 
change from arachidonic acid to thromboxane �2, so 
we can see a reduction of thromboxane �2 s´ levels. 
The action of the thromboxane �2 stimulates the se-
cretion and platelet aggregation. The effect goes on the 
platelet s´ half life, that it is around 7-10 days. The pre-
ventive dose is 75-150 mg/day and the therapeutic dose 
when an immediate antithrombotic effect is demanded 
is 300 mg/day. 
DIPY�ID�MOL (Persantin®)
Produce an inhibition of the phosphodiesterase enzyme. 
This enzyme catalyzes from cyclic adenosine mono-
phosphate (c�MP) to �MP, so c�MP increases inside 
the platelet, and cause a block of the platelet activity. It 
is a reversible effect and goes on 24 hours.
TICLOPIDINE (Ticlodone®, Tiklid®)
It is a platelet �DP receptor blocker. It s´ in the thieno-
pyridines group and it was the first. Is a non activated 
drug that when is activated produce the blocker of the 
platelet s´ �DP receptor. We use this drug in patients 
with resistance problems to �S�. It has a very impor-
tant secondary effect: neutropenia that normally is re-
versible. 
CLOPIDOG�EL  (Plavix®, Iscover®)
It is a thienopyridine with higher antiplatelet action than 
�S�. It has an irreversible effect during 7-10 days and 
less secondary effects than ticlopidine so we prefer to 
use it. It has a problem: is very expensive. We use it 
mainly in acute myocardial infarction (�MI) alone or 
with �S�. Sometimes we can see in some patients a 
variable response including resistance probably for a 
bad bioavailability (poor absorption, pharmacological 
interference), alterations in the platelet functions and 
another factors like smoking, hypercholesterolemia (2).
There are different studies that prove the efficacy of the 
treatment with the classical antiplatelets alone or dual 
antiplatelets therapy (3,4). They has a residual risk of 
ischemic diseases, high risk of bleeding and a variable 
antiplatelet effect, so it has done that scientist look for a 
new antiplatelets drugs mainly in the group of receptors 
p2y12 of the �DP inhibitors and in another groups.
New antiplatelets drugs. Pharmacological properties 
and therapeutic intructions. 
The most important therapeutic condition of the new 
antiplatelet drugs is to reduce the ischemic events wi-
thout increase the bleeding risk. The usual indication 
of these drugs is for the management of thrombotic di-
seases that we can see in: acute coronary syndromes, 
ischemic stroke and TI�, peripheral artery disease and 
percutaneous coronary intervention.
PRASUGREL (CS-747, LY640315) (Efient®)
It is a third generation thienopyridine. Is an antiplate-
let drug the most fast and powerful and we can see the 
effect 30 minutes after it will be administrated (5). It 
will be introduced in the clinic practice for the throm-
bosis prevention after of percutaneous coronary inter-
vention (6). The clinic efficacy has been evaluated in 
the TRITON-TIMI 38 study where we can see the effi-
cacy of prasugrel and �S� compared to clopidogrel and 
�S�. The results of this study demonstrated than the 
incidence of cardiovascular death, �MI, and stroke are 
less, but we observe a major tendency of bleeding, in-
cluding fatal ending (7), above all in patients older than 
75 yeas old, weight less than 60 kilograms and patients 
with previous stroke or TI� (4) and/or coronary by pass 
surgery (6), so we must avoid using this drug in this 
patients (5). 
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Prasugrel doesn t´ have pharmacological interaction 
with proton pump inhibitors (lansoprazole, omeprazo-
le, etc), and neither with inductors of this proton pump: 
rifampicin, carbamazepine, ketoconazole, verapamil, 
diltiazem, ciprofloxacine and clarithromycin. (4,8). It is 
the first choice in diabetic patients because they show 
an increase in platelet reactivity and a less response to 
clopidogrel.  By the way, we don t´ need to adjust the 
dose in renal failure (4).
TIC�G�ELO� (�ZD6140) (Brilique®)
It s´ a new reversible direct inhibitor of the P2Y12 recep-
tor and is included in the nonthienopyridine group.  It 
has a very fast action (complete platelet inhibition in 2 
hours) and the inhibition disappears in 12 hours approxi-
mately (3). The efficacy of ticagrelor was evaluated in 
the PL�TO study, with �S� and ticagrelor compared to 
an �S� and clopidogrel.  They observe a less incidence 
of cardiovascular death, �MI, and stroke. They don t´ 
find a major tendency of bleeding, but they observe after 
30 days an increase of bleeding not related with coronary 
by passes after 30 days (9,10). It has some adverse effects: 
dyspnea, and increase in serum of uric acid and creatini-
ne (3). Ticagrelor has an oral administration.
C�NG�ELO� (��-C69931) (6).
It is an antagonist of the platelet �DP s´ receptors. It has 
a very short answer and produces a reversible platelet in-
hibition. The way of administration is intravenous, so the 
effect is immediate. It makes that cangrelor is used when 
we need antiplatelet effect during perioperative time.
ELINOG�EL (P�T060128)
It is a new reversible direct inhibitor of the P2Y12 re-
ceptor for the �DP. The way of administration can be 
oral or intravenous. The effect is immediate if we admi-
nistrate it intravenously during 12 hours. We can find 
adverse effects like dyspnea and increase in serum of 
transaminases (3,6).
OTHE�S
Presently a new group of inhibitors of the platelet P��-1 
receptor is being developed (is a thrombin receptor). In 
this group we can include: terutroban, atopaxar (E5555) 
y varopaxar (SCH-530348) (3,6).
Anticoagulant Drugs 
-Classics anticoagulant drugs 
HEP��IN
It is a linear mucopolysaccharide, whose action appears 
when it binds to antithrombin III, accelerating its reac-
tion. The antithrombin III is a potent inhibitor of the 
thrombin. Other coagulation components can be inacti-
vated like IXa, Xa, XIa, XIIa factors and plasmin. We 
can measure its effect with the activated partial throm-
boplastin time (aPTT).
�t this moment we use low molecular weight heparin 
(LMWH) because it has a high half life of 4 hours (nor-
mally heparin has a half life of 1-2 hours). It is elimina-
ted completely in 24 hours, making easy the manage-
ment. It has a parenteral way of administration. We use 
LMWH in cases we need anticoagulation or thrombosis 
prevention for a limited time. Due to the disadvantage 
of the way of administration and the secondary effects 
appears if it is administrated for a longer period than 6 
months (thrombocytopenia, osteoporosis). It has an an-
tidote: protamine sulphate, so we can use heparin for 
bridge therapy to oral anticoagulants in surgery and 
prolonged immobilization (11).
W��F��IN (�ldocumar®) Y �CENOCOUM��OL 
(Sintrom®)
Warfarin and acenocoumarol are oral anticoagulant 
drugs of the coumarin group. Warfarin is used in �n-
glo-Saxon countries, and in Spain we normally use 
acenocoumarol (12).
Its way of action is the same: vitamin K antagonist 
drugs so they reduce the hepatic synthesis of the factors 
of vitamin K coagulation: II, VII, IX and X, as well as 
C and S proteins. Its effect is not immediate but requi-
res several days to get it. �s pharmacokinetics qualities: 
they present a good oral absorption, a high tendency to 
union to plasmatic proteins, an hepatic and renal meta-
bolism and a half-life between 10 and 24 hours. These 
characteristics make possible a great number of factors 
which take part in its absorption and that can modify 
the potential of action. They also present a great number 
of drug interactions.
Its anticoagulant effect is measured by the prothrom-
bin time (PT). �s there were differences between many 
laboratories, in 1978 the World Health Organization 
(WHO) recommended to standardize PT and in 1983 
the IN� (International Normalized �atio) was intro-
duced, being the quotient between TP s´ patient and the 
TP standardized by the laboratory or control (13,12). Its 
normal accepted value for the control of the anticoagu-
lation requested in different clinic entities is around 2 
and 3.5, so it s´ recommended to be between 2 and 3 in 
illnesses like the prevention of venous thromboembo-
lism, prevention of systemic embolism in cases of some 
arrhythmia as �F, etc., and between 2.5 and 3.5 like 
in the case of heart valve prosthesis, recurrent systemic 
embolism and recurrent �MI (12).
-New anticoagulant drugs. Pharmacological characte-
ristics  and therapeutic indications
In the last years, pharmaceutical industry has developed 
new anticoagulant drugs, which produce a more selec-
tive effect on coagulation components, an easier way 
of use so a reduction of possible complications. The 
main indications of new anticoagulant drugs are the 
prevention of strokes and systemic embolism in cases 
of some arrhythmia as �F, just like the prevention of 
venous thromboembolism in patients after elective hip 
or knee replacement surgery. CH�DS2 score is a try to 
quantify stroke and TI� risk in patients with �F, to va-
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lue if anticoagulation is required, where C is congestive 
heart failure, H hypertension, � age > or = 75 years, D 
diabetes y S stroke or TI�. Each letter punctuate one 
point, except S that its presence which means 2 points. 
The scoring range is between 0 and 6. � 2 point score 
forces the need of anticoagulation. �ecently there has 
been added other risk factors, changing the scale to 
CH�DS2-V�Sc, where V is vascular diseases, � is the 
age between 65 and 74 and Sc is female gender. (14). In 
this group of drugs we can note:
XIMEL�G�T��N (15) (Exanta®)
It is the first competitive and direct thrombin inhibitor. Its 
efficiency and safety were valued in the SPORTIFF III y 
V study where was compared to warfarin. �n identical 
efficacy was found in the prevention of stroke and TIA 
in patients with non valvular �F and with some vascular 
risk factor added. It was also observed that It didn t´ have 
a greatest tendency to bleeding, although It was removed 
from the market because of its hepatotoxicity.
D�BIG�T��N (16) (Pradaxa®)
It s´ administrated like dabigatran etexilate (inactive), 
which is a pro-drug transformed to dabigatran (active) 
by the hydrolysis of plasmatic and hepatic esterases. It 
is a competitive and reversible thrombin inhibitor, inhi-
biting the reaction from fibrinogen to fibrin, so inhibits 
the thrombus formation. So it also inhibits free thrombin, 
thrombin linked to fibrin and antiplatelet effect induced 
for thrombin. In Spain we use it for: primary prevention of 
venous thromboembolism in patients after elective hip or 
knee replacement surgery, , stroke prevention and syste-
mic embolism prevention in non valvular �F  in patients 
with one or more of these factors: stroke, TI� or previous 
systemic embolism, ventricular ejection fraction < 40%, 
symptomatic heart failure > or = Class II of the New York 
Heart �ssociation (NYH�) scale, age > or = 75 years and 
age > or = 65 years related to one of the next diseases: 
diabetes, coronary disease or hypertension.
Efficiency and security have been evaluated in RE-LY 
study, where is compared dabigatran etexilate from 
warfarin in patients with �F with moderate or high risk 
of stroke, TI� or systemic embolism, with two doses: 
110 mg/twice a day and y 150 mg/twice a day. They 
have demonstrated a similar efficiency to warfarin wi-
thout higher bleeding tendency with doses of 110 mg/
twice a day. With doses of 150 mg/twice a day, they 
have demonstrated a higher efficiency in reduction of 
ischemic and hemorrhagic stroke, vascular death, in-
tracranial hemorrhagic and total bleeding compared to 
warfarin, although the �MI indexes were higher. The 
secondary effect more frequent was bleeding in a 16,5 
% of the patients. Other adverse effects were: epistaxis, 
anemia, gastrointestinal haemorrhage, abdominal pain, 
diarrhea, dyspepsia and nausea (17).
It has a renal elimination above all, so the renal function 
will be controlled. In case of renal failure increases the 
incidence of bleeding. Other factors that increase he-
morrhagic risk are: age >75 years, low bodyweight, 
pharmacological interactions, etc. Dabigatran is contra-
indicated in mechanical heart valve prosthesis, severe 
renal failure with creatinine clearance < 30 ml/min. We 
need to be careful in patients with moderate renal failu-
re (createnine clearance between 30-50 ml/min).
If we administrate dabigatran with glycoprotein-P inhi-
bitors (amiodarone, verapamil, quinidine, ketoconazole 
and clarithromycin) can increase the dabigatran’s effect, 
and if we administrate it with glycoprotein-P inducers 
(rifampicin, St. �ohn, s herb, carbamazepine, phenytoin) 
the effect decreases.
Dabigatran changes coagulation tests like aPTT, PT, 
thrombin time (TT) and ecarin time (in experimental 
phase). In case of emergency we can use the TT to value 
the dabigatran’s effect (15).
New anticoagulants lack specific antidote, so in emer-
gency situations that need reduction or anticoagulation s´ 
cessation (important haemorrhages, etc.), makes difficult 
its use. In the case of dabigatran it is been proposed the ad-
ministration of active carbon for reducing the absorption 
of the drug, and the use of hemodialysis for increasing its 
elimination (15,18). It’s been also suggested the adminis-
tration of blood transfusion or fresh plasma (19).
�IV��OX�B�N (Xarelto®)
It s´ a competitive, reversible and direct inhibitor from 
coagulation factor Xa (17).
 Its therapeutic indications in the United States and in 
Europe include: prevention of venous thromboembo-
lism in patients after elective hip or knee replacement 
surgery, prevention of stroke , TI� or systemic embo-
lism, non valvular �F with one or more of the following 
factors:  congestive heart failure, hypertension, age > or 
= 75 years, diabetes, stroke or TI� previous. Nowadays 
it s´ been investigated its use in the treatment of lung 
thromboembolism and the prevention of the recurrent 
episodes (17).
Its efficiency and safety have been valued in the ROC-
KET �F study, where it s´ compared to warfarin in pa-
tients with non valvular �F, moderate or high risk of 
stroke or systemic embolism.  
It lacks a valid monitoring method for testing its effi-
cacy, altering the aPTT and even more the PT, so this 
last one is used for quantifying its effect (15).
�PIX�B�N (Eliquis®)
It action consist, as the rivaroxaban, in a selective inhi-
bition of the coagulation factor Xa. It s´ been investigated 
its use in the treatment of deep venous thrombosis, acute 
pulmonary thromboembolism and prevention of recu-
rrent episodes. (17). It s´ been also valued its use in unsta-
ble angina for preventing cardiac ischemic episodes.
Its efficacy has been proved in two recent studies: AVE-
��OES and ��ISTOTLE. These studies conclude that 
apixaban presents a higher efficiency in the prevention 
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of stroke and systemic embolisms than �S� and war-
farin respectively, not objectifying a greater bleeding 
incidence and less mortality. 
EDOX�B�N (Lixiana®)
It is a direct and specific inhibitor of factor Xa. It s´ been 
investigated its use in deep venous thrombosis, pulmo-
nary thromboembolism, and in the prevention of embo-
lic episodes in patients with �F. It s´ widely eliminated 
by urinary tract so its dose must be settled in case of 
renal failure (20).
BET�IX�B�N
It is a direct inhibitor of factor Xa. It s´ been investigated 
its use in the prevention of embolic episodes in patients 
with �F. Its main elimination is the biliary tract, only 
eliminating 5% through the urine so it could be indica-
ted for patients with renal failure (20).
Every direct inhibitors of coagulation factor Xa, pre-
viously enumerated, have an oral way of administration 
(17).
OT�MIX�B�N
It s´ a potent and selective inhibitor factor Xa with an 
intravenous way of administration (17). 
Odontostomatologial treatments in patients with 
classic antiplatelets and anticoagulantspautas 
-Dental management in patients with classic antipla-
telets: 
The attention guidelines in the dental cabinet of patients 
with classic or new antiplatelets, don t´ differ at all consi-
dering that there aren t´ any studies with the new drugs. 
We have to compare the measures of the old ones to the 
new generation. In the bibliographic revision we haven t´ 
found randomized essay not even cohort studies where 
the dental management of patients under a treatment 
with new antiplatelets is valued and limited studies 
where the classic antiplatelet are valued in the dental 
practice (21). We agree with the material published in 
the Guidelines of the �merican College of Chest Phy-
sicians about perioperative management of antithrom-
botic therapy (22).
-Dental management in patients with classic anticoagu-
lants: 
Throughout the history of the use of anticoagulant drugs 
in the medical practice, it has been seen an evolution in 
protocols of dental management of these patients. �t 
first there were protocols that recommended replacing 
the anticoagulant drug (warfarin or acenocoumarol) for 
low molecular weight heparin (LMWH) with different 
possibilities.
In these patients we must considerate the risk of throm-
bosis if we suppress the anticoagulant therapy, facing 
the risk of bleeding if we don t´ do it. In the review ar-
ticle of Pototski et al. (1), marks that the thrombosis 
tendency in the different revised studies is between the 
0.02% and the 1% for minor methods like dental ex-
traction meanwhile the risk of bleeding is between the 
0% and the 3.5% according to the studies. The problem 
is that the possibility of fatal ending is more probable 
in the case of thrombosis appearance, than in the case 
of haemorrhage. Because of that, nowadays the studies 
recommend that in case of simple dental extraction of 
one or two teeth (contiguous or adjacents), not remov-
ing the anticoagulant drug (1,12,13,23-25). We must 
control the drug s´ anticoagulant action with the IN�, 
whose value has to be done at least 72 previous hours to 
the dental extractions, although it s´ better if it s´ done 24 
hours before. The IN� ideal value for doing the dental 
extractions is established in different studies between 
2 and 4, although it s´ widely accepted that the optimal 
value is in 2, 5 because this value minimises the risk of 
bleeding and thrombosis (1).
If we think that the dental extraction will be compli-
cated, flap and osteotomy is necessary or patients with 
multiple pathologies we can bridge anticoagulants with 
LMWH 2 or 3 days before dental surgery. We can do the 
same in patients with high thrombosis risk (24).
With these patients we must use local hemostatic ac-
tions like (1,12,23,25):
- Previously we have to remove irritation and inflamma-
tion of oral tissues, because bleeding tendency is higher. 
We can use oral hygiene tips, tartrectomy, chrohexidine 
rinses, etc.
-  We must do the dental extraction carefully trying to 
eliminate the less amount of bone tissue. 
- Curettage of the alveolus to eliminate granulation tis-
sue.
-  Irrigation of the alveolus with antifibrinolytics like 
tranexamic acid. 
- Use hemostatic sponges with fibrinogenous elements.
- Suture the wound with resorbable sutures preferably. 
If we use non resorbable sutures we have to remove in 
4-7 days. 
- Do compression with gauzes soaked with antifibrino-
lytics like tranexamic acid. 
- Bleeding control of the dentist. The patients must stay 
in the clinic alter the dental extraction at least 45-60 
minutes. 
- Mouth rinses with tranexamic acid.
- Patient’s control in days after surgery.
-Give writing post-extraction instructions (most of them 
were made by Scully y Cawson (1) including: control 
clot, not rinsing the mouth for 24 hours, not suck or ma-
nipulate the clot with the tongue, not to take hot drinks 
or hard food, etc. In case of bleeding the patients has to 
put a clean gauze soaked with antifibrinolytics like tra-
nexamic acid and make pressure; if after 20-30 minutes 
the bleeding doesn’t stop, the patient has to contact with 
the dentist. For this reason it is recommended to do the 
dental extractions in the morning and in the beginning 
of the week. 
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Variations of classic odontostomatologial treat-
ment guidelines in patients with new antiplate-
lets and anticoagulants
-Dental management in patients with new antiplatelets: 
In the dental management of the patients with antipla-
telets treatment we have to value two factors: the blee-
ding risk of dental treatment and the thrombotic risk of 
the disease that has needed antiplatelet treatment. The 
risk of bleeding conditioned that we have to use local 
hemostatic actions or not. The thrombotic risk conditio-
ned the possibility of modifying antiplatelet treatment.
 The principal action with bleeding risk is the dental ex-
traction. Normally a simple dental extraction has a low 
bleeding risk while a multiple dental extractions have a 
high risk of bleeding (24).  In the case of mucogingival 
surgery is low risk of bleeding if it isn’t very extensive. 
Sometimes is difficult to predict if the dental extraction 
will be simple or complicate. If there is an inflammatory 
process the risk of bleeding will be high (24).
The thrombotic risk will be established for the medical 
specialist of the patient because there are lots of factors 
that can condition it like: underlying disease, age, time 
from acute episodes, renal function, good medical con-
trol, etc. So the decision of removing or not the antipla-
telets treatment will be done by the medical specialist 
and not by the dentist or by the patient.
In the review article of  Hall �. y Mazer CD (6), about 
the perioperative use of patients under an antiplatelet 
treatment, indicate that in the case of existing during 
a surgical intervention, a risk of low bleeding and the 
risk of thrombosis (in this case: stent thrombosis) being 
high or moderate, they recommend not interrupting the 
antiplatelets treatment, but if the risk of thrombosis is 
low they recommend suppressing some of the antipla-
telet treatment in the case of being dual and recovering 
it as soon as possible. In the guide of the European So-
ciety of Gastrointestinal Endoscopy for the manage-
ment of patients with antiplatelet agents that need an 
endoscopy (26), made by Bosutière C, et al. They note 
that in methods with low risk of bleeding and risk of 
thrombosis like any other, it s´ recommended continue 
with the antiplatelet treatment. In case of methods with 
high risk of bleeding, they note removing the pharma-
cological antiplatelet treatment or replacing it, asking 
first the medical specialist. The reflected information in 
both studies could be comparable to dental management 
of patients when we are going to perform a simple den-
tal extraction, considering it a surgical act of low risk of 
bleeding (24).
There are numerous studies and publications where not 
suppressing the antiplatelet treatment is recommen-
ded in case of a surgical act with low risk of bleeding 
and especially in the case of a simple dental extraction 
(27,28,29). It s´ also of importance that most of the pu-
blished studies have been produced at patients who were 
having �S�, clopidogrel or both, because these two are 
the most used antiplatelet drugs nowadays. (27-29).  
We can establish as a possible practice guide of den-
tal management in patients under an antiplatelet 
treatment: 
- Establish the risk of bleeding. Simple dental extraction 
as low risk and multiple extractions as high risk (24). It s´ 
been determined in some studies the relation between 
the number of extractions and the bleeding tendency: in 
the study of Cardona-Tortajada F, et al. (28) established 
a connection statistically significant between the bleed-
ing and the number of extracted teeth, remarking that 
it s´ not recommended to perform more than 3 dental ex-
tractions in the same surgical act and that these must be 
of adjacent teeth. 
- Establish the thrombotic risk of the patient by the me-
dical specialist who controls the patient.
- �pplication of local measures for the control of the 
haemorrhage indicated before.  
-Dental management in patients with new anticoagu-
lants: 
The new anticoagulant drugs, as we have mentioned be-
fore, present advantages and disadvantages from classic 
vitamin K antagonist. Zapata Wainberg G et al. (15), in 
the advantages they find its few pharmacological and 
dietetic interactions, not requiring the monitoring of 
routine, its quick start of action, having less or simi-
lar bleeding rates, etc. In the disadvantages they also 
note not having specific antidotes in case of emergency 
situations for reversing the anticoagulant effect, a high 
price, some of them must be administrated two times 
a day and the lack of valid methods of monitoring for 
quantifying its effect. 
There have been published many articles about dental 
management with patients under treatment with clas-
sic anticoagulants (1,12,30). However, there are only a 
few studies about dental management in patients under 
treatment with the new anticoagulant drugs. In the last 
12 months have appeared in medical literature some ar-
ticles trying to establish a guideline for these patients, 
when we have to do them a dental treatment, although 
they also indicate the need of making clinic studies that 
support the protocols. 
We agree with the article of Spyropoulos �C. and Do-
uketis �D. (24) about the risk of bleeding, considering 
that simple dental extraction and minor surgery have 
a low risk of bleeding, however the multiple dental ex-
tractions have a high risk of bleeding, for this we re-
commend the dental extraction no more than 3 teeth 
in the same surgical act and they will be contiguous or 
adjacents . It is better if we do simple dental extraction 
(1,28). Because of all, considering that usually our acts 
are in low risk bleeding, and that there are numerous 
studies that recommend not removing anticoagulant 
anti vitamin K (1,12,30), we could think that with the 
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new anticoagulant drugs (dabigatran, rivaroxaban, etc.) 
it would not be necessary removing its during the dental 
treatment (31,32), although, as we have indicated pre-
viously, there are not any studies that support this parti-
cular way of acting, and we must be prudent. 
We classify the thromboembolisn risk in patients with 
the new anticoagulants (remember that the main indi-
cation is non valvular �F) in 3 groups (24): the risk is 
high when we have a CH�DS2 score of 5 or 6, stroke or 
recent TI� (< 3 months) or history of rheumatic valve 
disease. � moderate risk if CH�DS2 score  is 3 or 4. 
Finally the risk is low if CH�DS2 score is between 0 
and 2 and there isn’t previous stroke or TI�.
Combining both factors we could say that in cases of 
high thromboembolism risk and low bleeding risk we 
shouldn’t remove new anticoagulant treatment (31,32). 
In case of low thromboembolism risk and high bleeding 
risk, the medical specialist who controls the patient 
should modify the new anticoagulant treatment. �n 
advantage of new anticoagulants (dabigatran, rivaroxa-
ban and apixaban) is that they have a reduced half life 
in patients with normal renal function, and in case of 
being necessary its removal, it will be done 24 hours 
before the surgical treatment. If renal function is wrong 
the removal will be done between 4 days and 24 hours 
in the case of dabigatran, and between 2 days and 24 
hours in the case of rivaroxaban, before surgery (19). 
Its reintroduction must be done as soon as possible if 
there isn’t bleeding, normally recommending to do it 
24 hours after surgical act. If there is a postoperative 
bleeding risk the reintroduction will be done after 2-3 
days from surgery (24) with normal dose. Other authors 
recommend the reintroduction as soon as possible with 
minimun bleeding surgery: 4-6 hours after the act, with 
half normal dose and increase it gradually (19). By the 
way it will be controlled for the medical specialist. With 
these patients we must use local hemostatic actions for 
minimizing bleeding risk.
�s some authors noted (33), in the dental treatment of 
anticoagulated patients we have to value different fac-
tors: kind of surgery, analytical values, medical spe-
cialist recommendations, oral and medical conditions 
of the patients. �ll of them must be considered before 
dental treatment, to minimize potencial risks and to get 
success in our treatments with them. 
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